What one share of Jasper Therapeutics holds
We are a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (“CSU”), Chronic
Jasper Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.23 |
|---|---|
| Cash and investments | $0.26 |
| Book value | $0.05 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$51.70 | — | — | — | — |
| 2021 | — | −$26.89 | — | — | — | — |
| 2022 | — | −$10.33 | — | — | — | $9.46 |
| 2023 | — | −$6.18 | — | — | — | $7.03 |
| 2024 | — | −$4.89 | — | — | — | $4.11 |
| 2025 | — | −$3.95 | — | — | — | $0.15 |
Common questions about Jasper Therapeutics
How much does one share of Jasper Therapeutics earn?
Over the last 12 months, Jasper Therapeutics lost $1.23 for each share.
Does Jasper Therapeutics pay a dividend?
Jasper Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Jasper Therapeutics’s book value per share?
Jasper Therapeutics’s book value is $0.05 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Jasper Therapeutics have?
Each share of Jasper Therapeutics has $0.26 of cash and investments, as of June 30, 2026.
Has Jasper Therapeutics bought back shares?
Jasper Therapeutics’s share count rose about 3029% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.